Literature DB >> 28835837

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

C Fielder Camm1, A John Camm2,3.   

Abstract

Hypertrophic cardiomyopathy (HCM) represents a common inherited cardiac disorder with well-known complications Including stroke and sudden cardiac death. There is a recognised association between HCM and the development of AF. This review describes the epidemiology of AF within the HCM population and analyses the risk factors for the development of AF. It further discusses the outcomes associated with AF in this population, including the evidence in support of higher stroke risk in patients with HCM with AF compared with the general AF population. Finally, the evidence and recommendations for anticoagulation in this patient group are addressed.

Entities:  

Keywords:  Hypertrophic cardiomyopathy; anticoagulation; atrial fibrillation; stroke

Year:  2017        PMID: 28835837      PMCID: PMC5522714          DOI: 10.15420/aer.2017.4.2

Source DB:  PubMed          Journal:  Arrhythm Electrophysiol Rev        ISSN: 2050-3369


  73 in total

1.  Long-term outcome in patients with apical hypertrophic cardiomyopathy.

Authors:  Maria J Eriksson; Brian Sonnenberg; Anna Woo; Paul Rakowski; Thomas G Parker; E Douglas Wigle; Harry Rakowski
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

2.  Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation.

Authors:  Y Doi; H Kitaoka
Journal:  J Cardiol       Date:  2001       Impact factor: 3.159

3.  Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.

Authors:  I Olivotto; F Cecchi; S A Casey; A Dolara; J H Traverse; B J Maron
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

4.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

Authors:  B J Maron; I Olivotto; P Spirito; S A Casey; P Bellone; T E Gohman; K J Graham; D A Burton; F Cecchi
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

6.  Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation.

Authors:  E J Gruver; D Fatkin; G A Dodds; J Kisslo; B J Maron; J G Seidman; C E Seidman
Journal:  Am J Cardiol       Date:  1999-06-17       Impact factor: 2.778

7.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.

Authors:  B J Maron; S A Casey; L C Poliac; T E Gohman; A K Almquist; D M Aeppli
Journal:  JAMA       Date:  1999-02-17       Impact factor: 56.272

8.  Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy.

Authors:  Akiyoshi Ogimoto; Mareomi Hamada; Jun Nakura; Tetsuro Miki; Kunio Hiwada
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

9.  A Review of Sudden Cardiac Death in Young Athletes and Strategies for Preparticipation Cardiovascular Screening.

Authors:  Michael C. Koester
Journal:  J Athl Train       Date:  2001-06       Impact factor: 2.860

10.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Iacopo Olivotto; Pietro Bellone; Maria Rosa Conte; Franco Cecchi; Björn P Flygenring; Susan A Casey; Thomas E Gohman; Sergio Bongioanni; Paolo Spirito
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

View more
  8 in total

Review 1.  Clinical presentations of hypertrophic cardiomyopathy and implications for therapy.

Authors:  Carles Díez-López; Joel Salazar-Mendiguchía
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

Review 2.  Follow-up and prognosis of HCM.

Authors:  Fernando Dominguez; Jorge Sanz-Sánchez; Pablo García-Pavía; Esther Zorio
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

3.  Anticoagulation in atrial fibrillation with factor X deficiency-A management dilemma.

Authors:  Jian Liang Tan; Kah Poh Loh; Danielle Fortuna; Arezoo Ghaneie
Journal:  Clin Case Rep       Date:  2018-07-22

Review 4.  Thromboembolism in Patients with Hypertrophic Cardiomyopathy.

Authors:  Lu Liu; Zheng Liu; Xiaoping Chen; Sen He
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

5.  Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy.

Authors:  Junya Komatsu; Ryu-Ichiro Imai; Yoko Nakaoka; Koji Nishida; Shu-Ichi Seki; Toru Kubo; Naohito Yamasaki; Hiroaki Kitaoka; Sho-Ichi Kubokawa; Kazuya Kawai; Naohisa Hamashige; Yoshinori L Doi
Journal:  Circ Rep       Date:  2021-04-06

6.  Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy.

Authors:  Evan F Shalen; Stephen B Heitner; Lana Al-Rashdan; Reyhaneh Akhavein; Miriam R Elman; Katherine L Fischer; Lucy Q Lin; Meghan Mannello; Babak Nazer; Howard K Song; Ahmad Masri
Journal:  ESC Heart Fail       Date:  2021-10-27

Review 7.  Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually.

Authors:  Xiaogang Zhu; Zhenhua Wang; Markus W Ferrari; Katharina Ferrari-Kuehne; Javed Bulter; Xiuying Xu; Quanzhong Zhou; Yuhui Zhang; Jian Zhang
Journal:  ESC Heart Fail       Date:  2021-09-08

8.  Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.

Authors:  Moumita Bhattacharya; Dai-Yin Lu; Ioannis Ventoulis; Gabriela V Greenland; Hulya Yalcin; Yufan Guan; Joseph E Marine; Jeffrey E Olgin; Stefan L Zimmerman; Theodore P Abraham; M Roselle Abraham; Hagit Shatkay
Journal:  CJC Open       Date:  2021-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.